MS2028 Week 7 Drug List (PDF)

+-----------------+-----------------+-----------------+-----------------+ | Week 7 | | | | +=================+=================+=================+=================+ | Drug | Mechanism | Clinical Uses | Adverse Effects | +---...

+-----------------+-----------------+-----------------+-----------------+ | Week 7 | | | | +=================+=================+=================+=================+ | Drug | Mechanism | Clinical Uses | Adverse Effects | +-----------------+-----------------+-----------------+-----------------+ | Tiotropium | Long-acting | COPD, asthma | Xerostomia | | | muscarinic | | | | | receptor | | | | | antagonist | | | | | (LAMA) | | | | | resulting in | | | | | bronchodilation | | | +-----------------+-----------------+-----------------+-----------------+ | Formoterol | Long-acting | Asthma, COPD | Anxiety, | | | beta-2 agonist | | tremor, | | | (LABA), relaxes | | tachycardia | | | bronchial | | | | | smooth muscle | | | +-----------------+-----------------+-----------------+-----------------+ | Albuterol | Short-acting | Asthma, COPD | Anxiety, | | | beta-2 agonist | | tremor, | | | (SABA) | | tachycardia, | | | | | lactic | | | | | acidosis, | | | | | hypokalemia | +-----------------+-----------------+-----------------+-----------------+ | Budesonide | Inhaled | Asthma, COPD, | Respiratory | | | corticosteroid, | eosinophilic | infections, | | | inhibits | esophagitis | thrush, | | | cytokine | | dysphonia | | | synthesis | | | +-----------------+-----------------+-----------------+-----------------+ | Prednisone | Glucocorticoid, | Asthma and COPD | Cushing | | | inhibits NF-KB, | exacerbations, | syndrome, | | | suppresses B | autoimmune and | hyperglycemia, | | | and T cell | inflammatory | myopathy, | | | function by | diseases | striae, | | | downregulating | | osteoporosis, | | | cytokine | | peptic ulcers, | | | transcription | | poor wound | | | | | healing, | | | | | psychosis, | | | | | cataracts, | | | | | avascular | | | | | necrosis | +-----------------+-----------------+-----------------+-----------------+ | Roflumilast | Phosphodiestera | Severe COPD | Abdominal pain, | | | se-4 | with frequent | weight loss, | | | inhibitor, | exacerbations | depression, | | | increases | | anxiety, | | | cyclic AMP | | insomnia | | | leading to | | | | | bronchodilation | | | | | , | | | | | decreased | | | | | airway | | | | | inflammation | | | +-----------------+-----------------+-----------------+-----------------+ | Montelukast | Leukotriene | Asthma, | Suicidality in | | | (LTD4) receptor | especially | adults, | | | antagonist | exercise-induce | nightmares, | | | | d | behavioral | | | | asthma | problems in | | | | | children | +-----------------+-----------------+-----------------+-----------------+ | Omalizumab | Monoclonal | Resistant | Anaphylaxis | | | antibody | asthma | | | | against IgE | | | +-----------------+-----------------+-----------------+-----------------+ | Paclitaxel | Hyperstabilizes | Solid tumors | Myelosuppressio | | | polymerized | | n | | | microtubules | | | | | prevents | | Neuropathy | | | mitotic spindle | | | | | breakdown | | Hypersensitivit | | | | | y | +-----------------+-----------------+-----------------+-----------------+ | Irinotecan | Inhibits | Small cell lung | Myelosuppressio | | | topoisomerase I | cancer (and | n | | | | other solid | | | | | tumors) | Diarrhea | +-----------------+-----------------+-----------------+-----------------+ | Gemcitabine | Cytidine analog | Solid tumors, | Myelosuppressio | | | that inhibits | including | n | | | ribonucleotide | non-small cell | (neutropenia), | | | reductase and | lung cancer | nausea and | | | DNA polymerase. | | vomiting | | | Incorporated | | | | | into DNA, | | | | | inhibiting | | | | | synthesis and | | | | | function. | | | +-----------------+-----------------+-----------------+-----------------+ | Cisplatin | Cross-links | Solid tumors | Peripheral | | | DNA, cell cycle | (including | neuropathy, | | | non-specific | lung), | Fanconi | | | | lymphomas | syndrome | | | | | (proximal | | | | | tubule | | | | | dysfunction), | | | | | ototoxicity | +-----------------+-----------------+-----------------+-----------------+ | Bevacizumab | Monoclonal | Non-small cell | Poor wound | | | antibody | lung cancer, | healing, | | | against VEGF, | colon cancer, | bleeding, | | | inhibits blood | renal cell | gastrointestina | | | vessel | carcinoma | l | | | formation | | perforation | +-----------------+-----------------+-----------------+-----------------+ | Pembrolizumab | PD-1 inhibitor; | Non-small cell | Autoimmunity | | | tumor cells | lung cancer, | (dermatitis, | | | with PD-L1 and | other solid | enterocolitis, | | | PD-L2 bind to | tumors | hepatitis, | | | PD-1 on T-cell | | pneumonitis, | | | to inactive | | hypophysitis, | | | them; this drug | | endocrinopathie | | | blocks that | | s) | | | interaction, | | | | | activating | | | | | immune system | | | +-----------------+-----------------+-----------------+-----------------+ | Erlotinib | Small molecule | Non-small cell | Rash, diarrhea | | | inhibitor of | lung cancer | | | | EGFR (epidermal | positive for | | | | growth factor | EGFR | | | | receptor) | | | +-----------------+-----------------+-----------------+-----------------+